
Jaime Mejia
Advertisement
Articles by Jaime Mejia


46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
3
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5
